Mylotarg在急性髓细胞白血病治疗中的应用
被引量：1
摘要
CD33在90％以上的急性髓细胞白血病患者及早期髓细胞表达,为急性髓细胞白血病的治疗提供了理想靶点。目前已用于临床试验的主要有未修饰的HuM195和与同位素偶联的HuM195以及药物偶联的Gemtuzumab Ozogamicin(GO、CMA-676、Mylotarg),其中以Mylotarg最具有应用前景。本文着重对Mylotarg的研究进展作一介绍。
出处
《国外医学（输血及血液学分册）》
2005年第2期140-143,共4页
Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
参考文献16
-
1Kay Grobe,Leland D,Powell LD,et al. Role of protein kinase C in the phosphorylation of CD33 (Siglec-3) and its effect on lectin activity. Blood,2002,99(9):3188-3196.
-
2Jilani I,Estey E,Huh Y,et al.Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol,2002,118(4):560-566.
-
3Voutsadakis IA. Gemtuzumab Ozogamicin (CMA-676,Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs,2002,13(7):685-692.
-
4Amico D,Barbui AM,Erba E,et al.Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase3. Blood,2003,101(11):4589-4597.
-
5Matsui H,Takeshita A,Naito K,et al.Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia,2002,16(5):813-819.
-
6Walter RB,Raden BW,Hong TC,et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.Blood,2003,102(4):1466-1473.
-
7Roland B,Brian W,Michelle R,et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood,2004,103(11): 4276-4284.
-
8Sievers E,Appelbaum F,Spielberger R,et al.Selective ablation of acute myeloid leukemia usingantibody-targeted chemotherapy: a phaseⅠstudy of an anti-CD33 calicheamicin immunoconjugate. Blood,1999,93(11): 3678-3684.
-
9Larson RA,Boogaerts M,Estey E ,et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia,2002,16(9):1627-1636.
-
10Francesco Lo-Coco,Giuseppe C,Massimo B,et al. Gentuzumab ozogamicin(mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood,2004,10(4):1182-1185.
同被引文献20
-
1滕有为,郑朝晖,江绍开.环状“烯－二炔”抗癌抗菌素的研究进展[J].合成化学,1994,2(4):295-319. 被引量：6
-
2杨秀萍.稀有放线菌产生的高效抗肿瘤抗生素[J].微生物学通报,1995,22(1):49-54. 被引量：2
-
3刘文.烯二炔类抗肿瘤抗生素的生物合成研究进展[J].世界科技研究与发展,2005,27(3):24-31. 被引量：7
-
4顾觉奋,袁瑞瑛.烯二炔类抗生素的研究新进展[J].药学进展,2005,29(10):433-439. 被引量：5
-
5Nitin K D,Philip F.Antibody-targeted chemotherapy with immunoconjugates of calicheamicin[J].Pharmacology,2003,3:386.
-
6Kecke E,Jonas N,Susanne M,et al.Cleavage of cellular DNA by ealicheamicin γ1[J].DNA Repair,2003,2:363.
-
7Egidio G,Katsunori T,Weidong D,et al.Theoretical simulation of the electronic circular dichroism spectrum of calicheamicin[J].Bioorg Med Chem,2005,13(17):5072.
-
8Sergio A,Roberto S.Monoclonal antibodies and immunoconjugates in acute myeloid leukemia[J].Best Pract Res Clin Haematol,2006,19(4):715.
-
9Trail P A,King H D,Dubowchik G M.Monoclonal antibody drug immunoconjugates for targeted treatment of cancer[J].Cancer Immunol Immunother,2003,52:328.
-
10Chadi N,Lynn M R,Mary B R,et al.Phase Ⅱ pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older[J].Leuk Res,2005,29(1):53.
二级引证文献4
-
1李伟,张忠伟,薛学温,江涛.以DNA为靶点的含糖基药物的研究进展[J].中国海洋药物,2010,29(2):49-54.
-
2钱璟.烯二炔类抗肿瘤抗生素的研究进展[J].中国现代药物应用,2012,6(22):124-125. 被引量：2
-
3张庆娟.烯二炔类抗肿瘤抗生素卡利奇霉素的研究进展[J].临床合理用药杂志,2013,6(28):177-178.
-
4石依冉,王岩,陈少欣.抗体-药物偶联药物的研究进展[J].世界临床药物,2013,34(12):755-759. 被引量：7
-
1孟景晔.Mylotarg治疗第一次复发的CD33^+急性髓系白血病患者的疗效和安全性[J].国外医学（内科学分册）,2003,30(2):82-82.
-
2胡元,黄仁魏,林东军,李旭东,何易,王文文.自体外周血造血干细胞移植联合Mylotarg治疗急性髓系白血病一例并文献复习[J].白血病．淋巴瘤,2009,18(1):38-39.
-
3FDA:辉瑞抗肿瘤药Mylotarg撤市[J].临床合理用药杂志,2010,3(13):110-110.
-
4程澍,李军民,沈志祥.抗CD33单克隆抗体在急性髓细胞性白血病中的应用[J].中国处方药,2005,4(8):44-47. 被引量：2
-
5谢荣华,范久波.急性髓细胞白血病患者血清LDH及IL-Ⅱ联合测定的临床意义[J].医学信息（西安上半月）,2006,19(4):686-687. 被引量：1
-
6黄梓伦.Mylotarg治疗髓性白血病2例[J].临床血液学杂志,2006,19(2):118-118.
-
7宋国丽,韩忠朝.抗CD33抗体在治疗急性髓系白血病中的应用[J].国外医学（输血及血液学分册）,2005,28(4):361-363.
-
8朱久进,谢家庆,王远亮,秦素华.高分子偶联靶向药物的研究进展[J].生物医学工程研究,2004,23(4):249-252. 被引量：2
-
9吴穗晶,杜欣,翁建宇,林伟,黄梓伦.CD33抗体治疗自体造血干细胞移植后复发急性髓性白血病2例[J].临床血液学杂志,2009,22(1):54-54.
-
10白血病治疗进展：抗体导向化疗[J].云南卫生科技与教育,2000,4(1):23-23.
